N/A N=103 Assessmet of Patients With PAH Right Ventricular Volume
Pulmonary Arterial Hypertension
Primary: Observed Mean (Std Err) for % Difference Between VMS and MRI. — 4.80; 1.76; 2.03 Percent difference
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Pleth Variability Index (PVI) as a Measure of Volume Status During Transcatheter Mitral Valve Repair
Mitral Regurgitation
Primary: Delta PVI to Delta LAP Correlation During MitraClip Placement — 4.30; -26.14 percentage of baseline (pre-MitraClip) — p=0.066
N/A N=100 PPV to Guide Fluid Management in the PICU
Sepsis · Systemic Inflammatory Response Syndrome
Primary: Total Fluid (ml/kg/Day) Given — 124.38; 122.099 ml/kg/day
N/A N=50 FAST PV and mGFR™ Technology in Congestive Heart Failure
CHF
Primary: Number of Participants With Treatment Related AEs and Serious Adverse Events (SAEs) — 0 Participants
N/A N=14 REmodeling the Left Ventricle With Atrial Modulated Pacing
Heart Failure
Primary: Number of Participants Who Remained on Study — 9; 4 participants
N/A N=50 The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
Mitral Regurgitation · Pulmonary Hypertension
Primary: Impaired Post-operative Functional Capacity — 35 Participants
Phase 4 N=75 Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)
Hypertension, Pulmonary
Primary: Change From Baseline to Week 24 in the Living With Pulmonary Hypertension (LPH) Questionnaire Total Score — -10.99 Scores
N/A N=30 Safety of the Nocturnal Passy Muir Valve and Impact on Sleep Quality at an LTACH Setting
Tracheostomy
Primary: Heart Rate — 84.10; 84.33 beats per minute — p=0.87
Phase 4 N=605 PreFER Managed Ventricular Pacing (MVP) For Elective Replacement
Cardiovascular Diseases
Primary: Time to Event Analysis: Number of Patients Who Experienced the First Cardiovascular Hospitalization Within 2 Years Post-implant — 43; 40 number of participants — p=0.72
N/A N=88 PECS II vs. MTP for Analgesia After MRM
Breast Neoplasm Female · Postoperative Pain Management
Primary: Post-operative Pain Severity Assessed by VAS at Hour-4 — 1.4; 2.2 score on a scale
N/A N=172 The Pathway PVD Study for Percutaneous Peripheral Vascular Interventions
Peripheral Artery Disease
Primary: Major Adverse Events (MAEs) Within 30 Days — 2 Participants
N/A N=171 Melody Transcatheter Pulmonary Valve Study: Post Approval Study of the Investigational Device Exemption Cohort
Congenital Heart Defects · Dysfunctional Right Ventricular Outflow Tract Conduits
Primary: Kaplan-Meier Freedom From TPV Dysfunction — 72.9 percentage of subjects — p=<0.0001
N/A N=10 Portable Pves Study
Lower Urinary Tract Symptoms
Primary: Accurate Vesical PRessure — 18.56; 17.45 cm H2O
Phase 3 N=274 A Precision and Accuracy Study of the Codman Valve Position Verification (VPV) System.
Hydrocephalus · Normal Pressure Hydrocephalus
Primary: Percentage of Participants Who Achieved "Adjustment Complete" and a Consensus X-ray Reading — 98.33 Percentage of participants
Phase 3 N=523 PreHospital Air Medical Plasma Trial
Hemmorhagic Shock During Air Medical Transport
Primary: Our Primary Outcome for the Proposal Will be 30 Day Mortality — 53; 89 Participants
N/A N=131 Melody® Transcatheter Pulmonary Valve Post-Approval Study
Dysfunctional Right Ventricular Outflow Tract (RVOT) Conduit
Primary: Acceptable TPV Hemodynamic Function at Six Months After Successful TPV Implantation — 96.7 percentage of patients
N/A N=1,745 Clinical Outcome of Pacemaker paTIents According to Pacing Modality and Primary INDications
Bradyarrhythmia
Primary: Two-year All-cause Mortality — 11 percentage of participants
N/A N=26 Does Endurance Improve With the Use of Passy-Muir Valve for Patients With Tracheostomy?
PMV · Exercise Endurance · Tracheostomy
Primary: Six Minute Walk Test - First Paired Sessions — 413; 387 Feet — p=0.2795
Phase 4 N=1,166 MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure
Atrial Fibrillation · Heart Failure, Congestive
Primary: Composite Endpoint Composed by Death for Any Cause, Cardiovascular Hospitalization or Permanent AF at 2 Years — 28.0; 23.1; 21.5 percentage of participants
Phase 2 N=30 Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study
Primary Mitochondrial Disease
Primary: Distance Walked on the 6-minute Walk Test (6MWT) by Visit — 394.1; 378.2 meters
N/A N=81 COMPASSION - COngenital Multicenter Trial of Pulmonic VAlve Regurgitation Studying the SAPIEN InterventIONal THV
Pulmonary Valve Insufficiency · Pulmonary Regurgitation · Dysfunctional RVOT Conduit
Primary: Freedom From Device or Procedure Related Death or Reintervention — 97.1 percentage of participants
N/A N=122 Evaluating the Safety and Efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for Treatment of Acute Pulmonary Embolism
Pulmonary Embolism · Acute Pulmonary Embolism
Primary: Change in Right Ventricle to Left Ventricle (RV/LV) Ratio Between Baseline and 48 Hours Post-procedure Assessed by Computed Tomography Angiography (CTA) — -0.45 ratio
N/A N=92 Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval Study
Ventricular Septal Defects
Primary: Primary Effectiveness End Point: Technical Success — 75 Participants
N/A N=33 Development of a Rehabilitation Strengthening and Mobility Program for Ventilator Dependent Older Patients
Respiration, Artificial · Critical Illness · Chronic Disease
Primary: Functional Assessment: Handgrip — 3.6; 1.3 kg
N/A N=566 Mode Of Ventilation During Critical IllnEss Pilot Trial
Respiratory Failure
Primary: Ventilator-free Days (VFDs) to Day 28 After Enrollment — 23; 22; 24 Ventilator-free days to day 28
N/A N=15 Mapping for Acute Transvenous Phrenic Nerve Stimulation Study
Sleep Apnea
Primary: Number of Patients With Response to Stimulation (Diaphragmatic Movement Achieved) — 15 Participants
N/A N=129 Premenstrual Hormonal and Affective State Evaluation (PHASE) Project
Premenstrual Dysphoric Disorder
Primary: Hormone Analysis — 70.7; 57.8; 114; 97.3 ng/mL
N/A N=103 The Effectiveness of AAD and IPV to Treat Hospitalized Infants (<2years) With Acute Viral Bronchiolitis.
Bronchiolitis
Primary: Length of Hospital Stay — 3.5; 3.6; 4.5 days
N/A N=67 Influence of IPV on GOR in Infants From 0 to 12 Months.
Gastro-oesophageal Reflux
Primary: Number of Refluxes — 0.48; 0.97 number of refluxes
N/A N=53 Electrical Stimulation in Patients With Prolonged Mechanical Ventilation
Respiratory Failure
Primary: Level of Activity of Daily Life — 25.2; 32.0 units on a scale — p=0.652